logo-loader

Tiziana Life Sciences chairman says start of dosing in coronavirus trial is 'monumental event'

Published: 02:54 02 Nov 2020 EST

Tiziana Life Sciences PLC's (LON:TILS) (NASDAQ:TLSA) chairman Gabriele Cerrone speaks to Proactive's Andrew Scott as it's about to begin dosing in its clinical study investigating nasally administered Foralumab in COVID-19 patients in Brazil. He says data from this trial is expected to available by the end of this year.

Tiziana Life Sciences reveals "exciting" clinical data from latest MS trial

Tiziana Life Sciences Ltd (NASDAQ:TLSA) chief medical officer and chief operating officer Matthew Davis speaks to Thomas Warner from Proactive after the clinical-stage biopharmaceutical company announced some fresh clinical results from its work in treating non-active secondary progressive...

on 10/16/2023